Comparing advanced heart imaging techniques in patients with specific types of heart attacks
Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA, Tako-Tsubo, SCAD, Myocarditis and NSTEMI in the Acute Phase and Post Convalescence
This study is testing new heart imaging techniques to see how well they can help people who have had certain types of heart attacks understand their heart function and improve their long-term health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zürich) |
| Trial ID | NCT06323811 on ClinicalTrials.gov |
What this trial studies
This clinical study investigates patients who experience acute myocardial infarction without significant coronary artery disease (MINOCA) and those with similar conditions (MINOCA-mimics) using advanced cardiac magnetic resonance (CMR) imaging. The study aims to evaluate microvascular function through a novel 3D myocardial perfusion imaging technique during the acute phase and after recovery. Participants will undergo imaging within 10 days of their event and again after three months to assess the diagnostic potential and prognostic significance of microvascular dysfunction and epicardial adipose tissue on cardiovascular outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals presenting with acute coronary syndrome symptoms, elevated cardiac biomarkers, and no significant coronary artery disease.
Not a fit: Patients with significant coronary artery disease or those with contraindications such as pacemakers or severe respiratory conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and treatment of patients with MINOCA and related conditions, leading to improved cardiovascular outcomes.
How similar studies have performed: Other studies utilizing advanced CMR imaging techniques have shown promise, suggesting potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * acute presentation with signs/symptoms of acute coronary syndrome or myocarditis * elevated cardiac biomarkers * no signficant coronary artery disease on coronary angiogram or coronary CT Exclusion Criteria: * pacemaker/other devices or claustrophobia * severe asthma, chronic obstructive lung or kidney disease * acute pulmonary embolism * arrhythmia on ECG * moderate to severe valvular disease
Where this trial is running
Zürich
- University Hospital Zurich — Zürich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Robert Manka, Prof. MD — University of Zurich
- Study coordinator: Robert Manka, Prof., MD
- Email: robert.manka@usz.ch
- Phone: +41442551251
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.